Today, an FDA advisory panel recommended that the COVID-19 vaccine candidate from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) be granted emergency use authorization (EUA). A total of 77% of the 22 panelists voted “yes” to issue an EUA for the vaccine.
In the past week, three countries — UK, Canada and Bahrain — granted emergency use of the vaccine.
But despite the promise of making available the first vaccine against the novel coronavirus in the U.S., a range of meeting participants recommended a careful approach.
Skepticism was most apparent in the open public hearing segment of the meeting when most speakers pointed to the need for more data on the vaccine candidate.
Get the full story from our sister site, Drug Discovery & Development.